Aptamer Group strikes deal with biotech firm for targeted genetic medicine development
Aptamer Group plc (AIM: APTA), a pioneering developer of Optimer binders, has announced a substantial agreement with an undisclosed biotechnology company focused on genetic medicine development. This collaboration underscores Aptamer Group’s growing influence in innovating life sciences through their cutting-edge technology.
Crafting Targeted Solutions for Genetic Medicines
Under this agreement, Aptamer Group will utilize its proprietary platform to discover Optimer binders specifically tailored for the targeting of genetic medicines to designated cell types. The development of these binders is crucial for the precise delivery of genetic treatments. Aptamer Group is set to receive up to £553,000 in development fees for this project, which is anticipated to start soon upon receipt of target materials from the customer and is expected to be completed within the current financial year.
Innovative Optimer Binders by Aptamer Group to Transform Genetic Medicine Targeting
The Promise of Optimer Binders
Optimer binders represent a novel class of molecules designed for selective targeting of new biomarkers and tissues. As fully synthetic oligonucleotide molecules, Optimers offer a controlled development process, yielding high affinity and selective binders. This makes them prime candidates for drug delivery applications. The smaller size of Optimers facilitates enhanced tissue penetration, which is essential for effective therapeutic delivery. Moreover, the precise control over Optimer conjugation to therapeutic payloads enables precision in therapeutic development and dosing.
Driving Forward Precision-Guided Therapies
Dr. Arron Tolley, Chief Technical Officer of Aptamer Group, highlighted the significance of this project in drug delivery, particularly within the genetic medicines space. He pointed out that targeting oligonucleotide therapeutics beyond hepatocytes is a widespread challenge in the industry. The unique properties of Optimers position them as suitable for developing precision-guided therapies, potentially representing a new frontier in targeted drug delivery.